- •Preface
- •Contents
- •Contributors
- •1 Primary Orbital Cancers in Adults
- •1.1 Lymphoproliferative Disorders
- •1.1.1 Presenting Signs and Symptoms, Histopathologic and Molecular Genetic Characteristics, and Diagnosis
- •1.1.2 Treatment
- •1.1.3 Follow-up
- •1.2 Mesenchymal Tumors
- •1.2.1 Fibrous Histiocytoma
- •1.2.2 Solitary Fibrous Tumor
- •1.2.3 Hemangiopericytoma
- •1.2.4 Other Mesenchymal Tumors
- •1.3 Lacrimal Gland Tumors
- •References
- •2 Nonmalignant Tumors of the Orbit
- •2.1 Presentation
- •2.2 Cystic Lesions
- •2.3 Vascular Tumors
- •2.4 Lymphoproliferative Masses
- •2.6 Mesenchymal Tumors
- •2.7 Neurogenic Tumors
- •2.8 Lacrimal Gland Tumors
- •References
- •3 Pediatric Orbital Tumors
- •3.1 Introduction
- •3.2 Cystic Lesions
- •3.2.1 Dermoid Cyst
- •3.2.1.1 Clinical Presentation
- •3.2.1.2 Imaging
- •3.2.1.3 Histopathology
- •3.2.1.4 Treatment
- •3.2.1.5 Prognosis
- •3.2.2 Teratoma
- •3.2.2.1 Clinical Presentation
- •3.2.2.2 Imaging
- •3.2.2.3 Histopathology
- •3.2.2.4 Treatment
- •3.2.2.5 Prognosis
- •3.3 Vascular Tumors
- •3.3.1 Capillary Hemangioma
- •3.3.1.1 Clinical Presentation
- •3.3.1.2 Imaging
- •3.3.1.3 Histopathology
- •3.3.1.4 Treatment
- •3.3.1.5 Prognosis
- •3.3.2 Lymphangioma
- •3.3.2.1 Clinical Presentation
- •3.3.2.2 Imaging
- •3.3.2.3 Histopathology
- •3.3.2.4 Treatment
- •3.3.2.5 Prognosis
- •3.4 Histiocytic Lesions
- •3.4.1 Eosinophilic Granuloma
- •3.4.1.1 Clinical Presentation
- •3.4.1.2 Imaging
- •3.4.1.3 Histopathology
- •3.4.1.4 Treatment
- •3.4.1.5 Prognosis
- •3.5 Neural Tumors
- •3.5.1 Optic Nerve Glioma
- •3.5.1.1 Clinical Presentation
- •3.5.1.2 Imaging
- •3.5.1.3 Histopathology
- •3.5.1.4 Treatment
- •3.5.1.5 Prognosis
- •3.5.2.1 Clinical Presentation
- •3.5.2.2 Imaging
- •3.5.2.3 Histopathology
- •3.5.2.4 Treatment
- •3.5.2.5 Prognosis
- •3.6 Malignant Lesions
- •3.6.1 Ewing Sarcoma
- •3.6.1.1 Clinical Presentation
- •3.6.1.2 Imaging
- •3.6.1.3 Histopathology
- •3.6.1.4 Treatment
- •3.6.1.5 Prognosis
- •3.6.2 Neuroblastoma
- •3.6.2.1 Clinical Presentation
- •3.6.2.2 Imaging
- •3.6.2.3 Histopathology
- •3.6.2.4 Treatment
- •3.6.2.5 Prognosis
- •3.6.3 Retinoblastoma
- •3.6.3.1 Clinical Presentation
- •3.6.3.2 Imaging
- •3.6.3.3 Histopathology
- •3.6.3.4 Treatment
- •3.6.3.5 Prognosis
- •3.6.4 Granulocytic Sarcoma
- •3.6.4.1 Clinical Presentation
- •3.6.4.2 Imaging
- •3.6.4.3 Histopathology
- •3.6.4.4 Treatment
- •3.6.4.5 Prognosis
- •3.6.5 Rhabdomyosarcoma
- •References
- •4.1 Introduction
- •4.2 Clinical and Radiological Presentation
- •4.3 Staging
- •4.4 Surgery
- •4.5 Chemotherapy
- •4.6 Radiation Therapy
- •4.7 Conclusions and Future Directions
- •References
- •5 Metastatic Orbital Tumors
- •5.1 Introduction
- •5.2 Incidence
- •5.3 Anatomical Considerations
- •5.4 Presentation and Clinical Features
- •5.5 Diagnosis
- •5.6 Treatment
- •5.7 Types of Cancer Metastatic to the Orbit
- •5.7.1 Breast Carcinoma
- •5.7.2 Lung Carcinoma
- •5.7.3 Prostate Carcinoma
- •5.7.4 Melanoma
- •5.7.5 Carcinoid Tumors
- •5.7.6 Other Cancers
- •5.8 Conclusion
- •References
- •6.1 Tumors of Intraocular and Ocular Adnexal Origin
- •6.1.1 Eyelid Tumors
- •6.1.2 Intraocular Tumors
- •6.2 Tumors of Sinus and Nasopharyngeal Origin
- •6.2.1 Squamous Cell Carcinoma
- •6.2.2 Other Tumors of Sinus and Nasopharyngeal Origin
- •6.3 Tumors of Brain Origin
- •6.3.1 Meningioma
- •6.3.2 Other Intracranial Tumors
- •References
- •7 Lacrimal Gland Tumors
- •7.1 Introduction
- •7.2 Lymphoproliferative Lesions of the Lacrimal Gland
- •7.3 Benign Epithelial Tumors of the Lacrimal Gland
- •7.3.1 Pleomorphic Adenoma
- •7.3.2 Other Benign Epithelial Tumors
- •7.4 Malignant Epithelial Tumors of the Lacrimal Gland
- •7.4.1 Adenoid Cystic Carcinoma
- •7.4.2 Other Malignant Epithelial Tumors
- •7.5 AJCC Staging for Lacrimal Gland Tumors
- •References
- •8.1 Introduction
- •8.2 Indications
- •8.3 Surgical Techniques
- •8.3.1 Medial Orbitotomy Approach
- •8.3.2 Medial Eyelid Crease Approach
- •8.3.3 Lateral Orbitotomy Approach
- •8.3.4 Lateral Canthotomy Approach
- •8.4 Possible Indications for ONSF in Cancer Patients
- •8.4.1 Metastatic Breast Cancer
- •8.4.2 Lymphomatous Optic Neuropathy Diagnosed by Optic Nerve Biopsy
- •8.4.3 Adjuvant Therapy in Optic Nerve Sheath Meningioma
- •8.4.4 Papilledema Associated with Brain Tumors
- •8.4.5 Radiation-Induced Optic Neuropathy
- •8.5 Complications of ONSF
- •8.6 Future Research
- •References
- •9 Management of Primary Eyelid Cancers
- •9.1 Introduction
- •9.2 Types of Eyelid Malignancies
- •9.2.1 Basal Cell Carcinoma
- •9.2.2 Squamous Cell Carcinoma
- •9.2.3 Melanoma
- •9.2.4 Sebaceous Gland Carcinoma
- •9.2.5 Other Primary Eyelid Malignancies
- •9.3 Management
- •9.3.1 Evaluation
- •9.3.2 Tumor Excision and Eyelid Reconstruction
- •9.3.3 Sentinel Lymph Node Biopsy
- •9.3.4 Nonsurgical Treatment
- •9.3.5 Follow-up
- •References
- •10 Management of Conjunctival Neoplasms
- •10.1 Introduction
- •10.2 Squamous Cell Neoplasms of the Conjunctiva
- •10.2.1 Conjunctival Intraepithelial Neoplasia
- •10.2.2 Invasive Squamous Cell Carcinoma
- •10.2.3 Management
- •10.2.3.1 Local Excision and Cryotherapy
- •10.2.3.2 Treatment of More Advanced Disease
- •10.2.4 Surveillance
- •10.3 Melanocytic Neoplasms
- •10.3.1 Nevus
- •10.3.2 Primary Acquired Melanosis
- •10.3.3 Conjunctival Melanoma
- •References
- •11 Surgical Specimen Handling for Conjunctival and Eyelid Tumors
- •11.1 Introduction
- •11.2 Communication with the Pathologist
- •11.3 Conjunctival Specimens
- •11.4 Eyelid Specimens
- •11.5 Mohs Micrographic Surgery
- •11.6 Summary
- •References
- •12 Neuroradiology of Ocular and Orbital Tumors
- •12.1 Introduction: Imaging and Protocol
- •12.2 Anatomy
- •12.3 Intraocular Lesions
- •12.3.1 Retinoblastoma
- •12.3.2 Uveal Melanoma
- •12.3.3 Uveal Metastases
- •12.4 Orbital Lesions
- •12.4.1 Lymphoma
- •12.4.2 Orbital Rhabdomyosarcoma
- •12.4.3 Orbital Nerve Sheath Tumors
- •12.4.4 Mesenchymal Tumors of the Orbit
- •12.4.5 Orbital Pseudotumor
- •12.4.6 Orbital Metastases
- •12.5 Optic Nerve Tumors
- •12.5.1 Optic Nerve Glioma
- •12.5.2 Optic Nerve Sheath Meningiomas
- •12.6 Lacrimal Gland Tumors
- •12.7 Secondary Tumor Spread to the Orbit
- •12.8 Periorbital Skin Cancer and Perineural Spread
- •12.9 Conclusion
- •References
- •13 Radiation Therapy for Orbital and Adnexal Tumors
- •13.1 Indications
- •13.2 Radiation Therapy Terminology
- •13.3 Radiation Therapy Techniques
- •13.4 Radiation Therapy for Squamous Cell Carcinoma of the Eyelid
- •13.5 Adjuvant Radiation Therapy for Ocular Adnexal Tumors
- •13.6 Radiation Therapy for Optic Nerve Meningiomas and Orbital Rhabdomyosarcomas
- •13.7 Toxic Effects of Radiation Therapy
- •13.8 Summary
- •References
- •14.1 Historical Perspective
- •14.2 Presentation and Workup
- •14.4 Genetics
- •14.5 Pathologic Features
- •14.6 Treatment Options
- •14.6.1 General Considerations
- •14.6.2 Enucleation
- •14.6.3 Chemoreduction
- •14.6.4 Subtenon (Subconjunctival) Chemotherapy
- •14.6.5 Unilateral Disease
- •14.6.6 Bilateral Disease
- •14.7 Focal Therapies
- •14.7.1 Cryotherapy
- •14.7.2 Laser Photocoagulation
- •14.7.3 Brachytherapy
- •14.7.4 Thermotherapy
- •14.7.5 Radiation Therapy
- •14.8 Multi-institutional Clinical Trials
- •14.9 Animal Models of Retinoblastoma
- •14.10 Gene Transfer Technology for Treatment of Retinoblastoma
- •14.11 Future Development
- •References
- •15 Management of Uveal Melanoma
- •15.1 Epidemiology
- •15.2 Clinical Features
- •15.3 Diagnosis
- •15.4 Staging and Prognostic Factors
- •15.5 Background Studies
- •15.6 Overview of Management
- •15.7 Brachytherapy
- •15.8 Charged-Particle Radiotherapy
- •15.9 Surgical Techniques
- •15.9.1 Uveal Resection
- •15.9.2 Enucleation
- •15.9.3 Transpupillary Thermotherapy
- •15.9.4 Pathologic Assessment
- •15.9.5 Histologic Examination
- •15.10 Conclusion
- •References
- •16 Uveal Metastases from Solid Tumors
- •16.1 Introduction
- •16.2 Patient Characteristics
- •16.3 Symptoms
- •16.4 Clinical Features
- •16.5 Diagnosis
- •16.6 Treatment
- •16.6.1 Observation
- •16.6.2 External-Beam Radiation Therapy
- •16.6.3 Chemotherapy
- •16.6.4 Plaque Brachytherapy
- •16.6.5 Transpupillary Thermotherapy
- •16.6.6 Enucleation
- •16.7 Prognosis
- •16.8 Conclusions
- •References
- •17 Vascular Tumors of the Posterior Pole
- •17.1 Introduction
- •17.3 Circumscribed Choroidal Hemangioma
- •17.4 Management of Posterior Choroidal Hemangiomas
- •17.5 Acquired Vasoproliferative Tumors of the Retina
- •17.6 Conclusions
- •References
- •18 Reconstructive Surgery for Eyelid Defects
- •18.1 Introduction
- •18.2 General Principles
- •18.3 Eyelid Defects Not Involving the Eyelid Margin
- •18.4 Small Defects Involving the Lower Eyelid Margin
- •18.5 Moderate Defects Involving the Lower Eyelid Margin
- •18.6 Large Defects Involving the Lower Eyelid Margin
- •18.7 Small Defects Involving the Upper Eyelid Margin
- •18.8 Moderate Defects Involving the Upper Eyelid Margin
- •18.9 Large Defects Involving the Upper Eyelid Margin
- •18.10 Lateral Canthal Defects
- •18.11 Medial Canthal Defects
- •References
- •19.1 Introduction
- •19.2 Anatomy
- •19.3 Causes of Obstruction
- •19.4 Evaluation
- •19.5 Treatment
- •References
- •20.1 Introduction
- •20.2 Ectropion
- •20.2.1 Ectropion Due to Facial Nerve Paralysis
- •20.2.2 Cicatricial Ectropion
- •20.3 Entropion
- •20.4 Ptosis
- •20.5 Eyelid Retraction
- •20.6 Periorbital Edema Secondary to Imatinib Mesylate
- •References
- •21.1 Introduction
- •21.2 Anatomic Considerations
- •21.2.1 Orbital Margin
- •21.2.2 Nasal and Paranasal Sinuses
- •21.2.3 The Lacrimal System
- •21.2.4 Maxilla
- •21.3 Repair of Orbital Defects
- •21.3.1 Overview of Approaches
- •21.3.1.1 Maxillectomy with Orbital Exenteration
- •21.3.1.2 Maxillectomy Without Orbital Exenteration
- •21.3.2 Types of Maxillary Defects and Strategies for Their Repair
- •21.3.2.1 Type I Defect
- •21.3.2.2 Type II Defects
- •21.3.2.3 Type III Defects
- •21.3.2.4 Type IV Defects
- •21.3.3 Reconstruction After Orbital Exenteration
- •21.4 Conclusion
- •References
- •22.1 Introduction
- •22.2 Surgical Technique
- •22.2.2 Resection of Optic Nerve in Patients with Retinoblastoma
- •22.2.3 Maintenance of Globe Integrity
- •22.3 Choice of Implant
- •22.4 Management of the Anophthalmic Socket After Enucleation and Radiation Therapy
- •22.4.1 Patients with Retinoblastoma
- •22.4.2 Patients with Uveal Melanoma with Microscopic Extrascleral Extension
- •22.4.3 Patients with Head and Neck Cancer
- •22.5 Evisceration
- •References
- •23.2 Indications
- •23.3 Preoperative Evaluation
- •23.4 Surgical Techniques of Orbital Exenteration
- •23.5 Reconstructive Options
- •23.6 Surgical Complications
- •23.7 Rehabilitation After Orbital Exenteration
- •Suggested Readings
- •24.1 Introduction
- •24.2 Relevant Anatomy
- •24.3 Clinical Evaluation
- •24.3.1 Evaluation of Muscle Function
- •24.3.2 Evaluation of Lacrimal Gland and Lacrimal Drainage System Function
- •24.4 Medical Management
- •24.5 Surgical Management
- •24.5.1 Treatment of Lagophthalmos and Exposure Keratopathy
- •24.5.2 Treatment of Lower Eyelid Laxity and Ectropion
- •24.5.3 Reanimation of the Midface
- •24.5.3.1 Static Reanimation
- •24.5.3.2 Dynamic Reanimation
- •24.5.4 Options for Correction of Brow Ptosis
- •24.5.5 Additional Procedures for Management of Facial Droop
- •24.6 Special Circumstances in Cancer Patients with Facial Nerve Paralysis
- •24.7 Conclusion
- •References
- •25.1 Introduction
- •25.4 Conclusions and Recommendations
- •References
- •26 Lacrimal and Canalicular Toxicity
- •26.1 Introduction
- •26.2 5-Fluorouracil
- •26.4 Docetaxel
- •26.5 Epiphora Associated with Other Chemotherapeutic Drugs
- •26.6 Conclusions
- •References
- •27.1 Introduction
- •27.2 Orbital, Periorbital, and Orbital Teratogenic Side Effects by Individual Drug
- •27.2.1 Busulfan
- •27.2.2 Capecitabine
- •27.2.3 Carmustine
- •27.2.4 Cetuximab
- •27.2.5 Cisplatin
- •27.2.6 Cyclophosphamide
- •27.2.7 Cytarabine
- •27.2.8 Docetaxel
- •27.2.9 Doxorubicin
- •27.2.10 Erlotinib
- •27.2.11 Etoposide
- •27.2.12 Fluorouracil
- •27.2.13 Imatinib Mesylate
- •27.2.14 Interferons
- •27.2.15 Interleukin-2, Interleukin-3, and Interleukin-6
- •27.2.16 6-Mercaptopurine
- •27.2.17 Methotrexate
- •27.2.18 Mitomycin C
- •27.2.19 Mitoxantrone Dihydrochloride
- •27.2.20 Plicamycin
- •27.2.21 Thiotepa
- •27.2.22 Vincristine
- •27.3 Summary
- •References
- •28.1 Introduction
- •28.2 Epidemiology
- •28.2.1 Bacterial
- •28.2.2 Viral
- •28.2.3 Fungal
- •28.3 Pathogenesis and Host Defense
- •28.4 Ocular and Orbital Manifestations of Infection
- •28.4.1 Bacterial
- •28.4.2 Viral
- •28.4.3 Fungal
- •28.4.3.1 Candida Species
- •28.4.3.2 Aspergillus Species
- •28.4.3.3 Other Fungal Species
- •28.5 Conclusion
- •References
- •29.1 Introduction
- •29.2 Ophthalmologic Findings with CN III, IV, and VI Palsies
- •29.3 CN III, IV, and VI Palsies due to Primary Cranial Nerve Neoplasms and Direct Extension from Primary Brain, Brain Stem, or Skull base Tumors
- •29.4 CN III, IV, and VI Palsies due to Metastasis to the Brain, Brain, Stem and Skull Base from Distant Sites
- •29.5 Cranial Nerve III, IV, and VI Palsies due to Head and Neck Cancers
- •29.6 Cranial Nerve III, IV, and VI Palsies due to Leptomeningeal Disease
- •29.7 Other Causes of CN III, IV, and VI Palsies in Cancer Patients
- •29.8 Conclusion
- •References
- •30 Skull Base Tumors
- •30.1 Introduction
- •30.2 Anatomy of the Skull Base
- •30.3 Imaging and Diagnosis of Skull Base Tumors
- •30.4 Skull Base Tumors and Neuro-ophthalmic Correlations
- •30.4.1 Esthesioneuroblastoma
- •30.4.2 Chordoma
- •30.4.3 Craniopharyngioma
- •30.4.4 Meningioma
- •30.4.5 Sinonasal and Nasopharyngeal Tumors
- •30.4.6 Schwannoma
- •30.4.7 Pituitary Tumors
- •30.4.8 Myeloma
- •30.4.9 Paraganglioma
- •30.4.10 Metastases
- •References
- •31.1 Optic Pathway Gliomas
- •31.1.1 Demographics and Presentation
- •31.1.2 Histopathology
- •31.1.3 Imaging and Lesion Location
- •31.1.4 Differential Diagnosis
- •31.1.5 Management
- •31.1.6 Prognosis
- •31.2 Optic Nerve Sheath Meningiomas
- •31.2.1 Incidence
- •31.2.2 Histology and Pathophysiology
- •31.2.3 Clinical Presentation
- •31.2.4 Imaging
- •31.2.5 Treatment
- •References
- •32 Leptomeningeal Disease
- •32.1 Introduction
- •32.2 Epidemiology
- •32.3 Clinical Presentation
- •32.3.1 LMD due to Solid Tumors
- •32.3.2 LMD due to Hematogenous Tumors
- •32.3.3 LMD due to Primary Brain Tumors
- •32.4 Diagnosis
- •32.4.1 Radiographic Imaging
- •32.4.2 Optic Neuropathies in LMD
- •32.5 Treatment
- •32.6 Prognosis
- •32.7 Conclusion
- •References
- •33 Paraneoplastic Visual Syndromes
- •33.1 Introduction
- •33.2 Pathogenesis
- •33.3 Carcinoma-Associated Retinopathy
- •33.4 Carcinoma-Associated Cone Dysfunction Syndrome
- •33.5 Melanoma-Associated Retinopathy
- •33.6 Autoimmune Retinopathy
- •33.7 Paraneoplastic Optic Neuropathy
- •33.8 Diagnostic Testing
- •33.9 Differential Diagnosis
- •33.10 Treatment and Prognosis
- •33.11 Conclusion
- •References
- •34.1 Introduction
- •34.2 NF1 and the Optic Pathway
- •34.3.1 Description and Clinical Issues
- •34.3.2 Evaluation and Management
- •34.4 Intraorbital Optic Nerve Glioma
- •34.4.1 Description and Clinical Issues
- •34.4.2 Evaluation and Management
- •34.5 Chiasmal and Hypothalamic Glioma
- •34.5.1 Description and Clinical Issues
- •34.5.2 Evaluation and Management
- •34.6 Intraparenchymal Astrocytoma
- •34.6.1 Description and Clinical Issues
- •34.6.2 Evaluation and Management
- •34.7 Conclusion
- •References
- •35 Other Optic Nerve Maladies in Cancer Patients
- •35.1 Introduction
- •35.2 Optic Neuropathies Related to Elevated ICP
- •35.2.1 Causes of Elevated ICP
- •35.2.2 Treatment of Elevated ICP
- •35.4 Optic Neuropathies Caused by Drugs
- •35.4.1 Optic Disc Edema Secondary to Drug-Induced Elevated ICP
- •35.4.1.1 Retinoids
- •35.4.1.2 Imatinib Mesylate
- •35.4.1.3 Cyclosporine A
- •35.4.1.4 Cytarabine
- •35.4.2 Elevated ICP Secondary to Cerebral Venous Thrombosis
- •35.4.2.1 Cisplatin
- •35.4.2.2 L-Asparaginase
- •35.4.3 Optic Disc Edema Usually Without Elevated ICP
- •35.4.3.1 Cisplatin
- •35.4.3.2 Carboplatin
- •35.4.3.3 Carmustine
- •35.4.3.4 Vincristine
- •35.4.3.5 5-Fluorouracil
- •35.4.3.6 Cyclosporine A
- •35.4.3.7 Tacrolimus
- •35.4.4 Optic Neuropathy Without Disc Edema
- •35.4.4.1 Fludarabine
- •35.4.4.2 Tacrolimus
- •35.4.4.3 Paclitaxel
- •35.4.4.4 Methotrexate
- •35.4.4.5 Cytarabine
- •35.5 Optic Neuropathies Caused by Radiation
- •References
- •36 Management of Endogenous Endophthalmitis
- •36.1 Introduction
- •36.2 Epidemiology
- •36.3 Microbiology
- •36.4 Clinical Manifestations and Diagnosis
- •36.5 Treatment
- •36.5.1 Bacterial Endophthalmitis
- •36.5.2 Fungal Endophthalmitis
- •36.5.2.1 Yeast Endophthalmitis
- •36.5.2.2 Mold Endophthalmitis
- •36.6 Prognosis
- •36.7 Summary
- •References
- •37 Viral Retinitis in the Cancer Patient
- •37.1 Introduction
- •37.2 Epidemiology
- •37.3 Clinical Features
- •37.3.1 CMV Retinitis
- •37.3.2 Acute Retinal Necrosis
- •37.3.3 Progressive Outer Retinal Necrosis
- •37.4 Treatment
- •37.4.1 CMV Retinitis
- •37.4.1.1 Intravitreal Injections
- •37.4.1.2 Ganciclovir Implant
- •37.4.2 Acute Retinal Necrosis
- •37.4.3 Progressive Outer Retinal Necrosis
- •37.5 Role of Vitreoretinal Surgery in Viral Retinitis
- •37.5.1 Argon Laser Photocoagulation
- •37.5.2 Retinal Detachment Repair
- •37.6 Prognosis
- •37.6.1 CMV Retinitis
- •37.6.2 Acute Retinal Necrosis
- •37.6.3 Progressive Outer Retinal Necrosis
- •37.7 Conclusion
- •References
- •38.1 Introduction
- •38.2 Indications for Diagnostic Vitrectomy
- •38.2.1 Vitreous Biopsy
- •38.2.2 Uveal Biopsy
- •38.3 Preoperative Considerations
- •38.3.1 Thrombocytopenia
- •38.3.2 Anesthesia
- •38.4 Vitreous Biopsy
- •38.4.1 Technique
- •38.4.2 Effect of Vitrector Gauge on Vitreous Sample
- •38.5 Uveal Biopsy
- •38.5.1 Technique
- •38.5.2 Complications
- •38.5.3 Collaboration with Pathology
- •38.6 Pathologic Processing
- •38.6.1 Cytology
- •38.6.2 Interleukin Measurement
- •38.6.3 Polymerase Chain Reaction
- •38.6.4 Genetic Analysis
- •38.6.5 Cytogenetic Uveal Melanoma Studies
- •38.7 Results of Diagnostic Vitrectomy
- •38.7.1 Common Diagnoses
- •38.7.2 Diagnostic Utility
- •38.8 Postoperative Considerations
- •38.9 Conclusion
- •References
- •39.1 Introduction and Epidemiology
- •39.2 Presentation and Diagnosis
- •39.3 Management
- •39.4 Future Considerations
- •39.5 Conclusions
- •References
- •Index
Ophthalmic Oncology
M. D. ANDERSON SOLID TUMOR ONCOLOGY SERIES
Series Editor: Raphael E. Pollock, M.D., Ph.D.
PUBLISHED VOLUMES
Liver Cancer
Edited by STEVEN A. CURLEY, M.D.
Breast Cancer
Edited by S. EVA SINGLETARY, M.D.
Pancreatic Cancer
Edited by DOUGLAS B. EVANS, M.D., PETER W.T. PISTERS, M.D., and JAMES L. ABBRUZZESE, M.D.
Bita Esmaeli
Editor
Ophthalmic Oncology
13
Editor
Bita Esmaeli
The University of Texas
M.D. Anderson Cancer Center Section of Ophthalmology Department of Head and Neck Surgery Houston, TX 77030, USA besmaeli@mdanderson.org
Series Editor
Raphael E. Pollock
The University of Texas
M.D. Anderson Cancer Center
Houston, TX, USA
ISBN 978-1-4419-0373-0 e-ISBN 978-1-4419-0374-7 DOI 10.1007/978-1-4419-0374-7
Springer New York Dordrecht Heidelberg London
Library of Congress Control Number: 2010934256
© Springer Science+Business Media, LLC 2011
All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden.
The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.
While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
Printed on acid-free paper
Springer is part of Springer Science+Business Media (www.springer.com)
Preface
A little over a decade ago, I had the privilege of helping to establish the first full-time ophthalmic oncology service based at a Comprehensive Cancer Center in the United States. Our Ophthalmic Oncology Service at The University of Texas M.D. Anderson Cancer Center has grown to include 4 subspecialty areas of ophthalmology: orbital oncology/oculoplastic surgery, ocular oncology, ocular surface diseases, and neuro-ophthalmology. Ophthalmic Oncology grew from faculty’s unique experiences and observations in their ophthalmology subspecialty areas at M.D. Anderson. The book highlights the unique aspects of ophthalmic oncology as a surgical and medical discipline practiced at a Comprehensive Cancer Center. The multidisciplinary management of ocular, orbital, and ocular adnexal (eyelid, conjunctival, and periocular soft tissues) cancers is emphasized, as well as the current recommendations and practices at our institution. In addition, ocular conditions caused as a direct result of cancer treatment are reviewed using illustrative photographs and case presentations. The authors include ophthalmology faculty members, current and former M.D. Anderson fellows, and experts in complementary disciplines such as radiation oncology, dermatopathology, ophthalmic pathology, radiology, plastic surgery, and other surgical subspecialties.
With an abundance of clinical photographs, clinicians will be able to correctly diagnose cancers of the orbit, eye, and ocular adnexal structures.
I appreciate the contributions of each of the authors who took time out of their busy schedules to meet the deadlines for this project. I particularly thank my three ophthalmology colleagues at M.D. Anderson, Dr. Dan Gombos, Dr. Stella Kim, and Dr. Jade Schiffman, who not only have helped put together some of the sections in this book as section editors and authors but also because of their unique contributions to the growth of our program in Ophthalmic Oncology at M.D. Anderson. My special gratitude goes to Stephanie Deming and Sue Moreau from the Department of Scientific Publications at M.D. Anderson for their tireless long hours of editing for this book. I also would like to thank Dr. Raphael Pollock for the opportunity to organize and lead this effort and the privilege to edit this book in the M.D. Anderson Solid Tumor Oncology Series. Finally, I am grateful for the support provided by the dedicated staff at Springer—Stacy Lazar, Maureen Tobin, and Laura Walsh.
Bita Esmaeli
Houston, Texas
v
Contents
Part I |
Orbital and Adnexal Oncology |
|
|
|
|
Section Editor: Bita Esmaeli |
|
1 |
Primary Orbital Cancers in Adults . . . . . . . . . . . . . . . . . . |
3 |
|
|
Roman Shinder and Bita Esmaeli |
|
|
2 |
Nonmalignant Tumors of the Orbit . . . . . . . . . . . . . . . . . . |
13 |
|
|
Eric M. Hink and Vikram Durairaj |
|
|
3 |
Pediatric Orbital Tumors . . . . . . . . . . . . . . . . . . . . . . . |
23 |
|
|
Jonathan J. Dutton and George K. Escaravage |
|
|
4 |
Multidisciplinary Management of Orbital Rhabdomyosarcoma . . |
61 |
|
|
Winston W. Huh and Anita Mahajan |
|
|
5 |
Metastatic Orbital Tumors . . . . . . . . . . . . . . . . . . . . . . . |
69 |
|
|
Syed Mehdi Ahmad and Bita Esmaeli |
|
|
6 |
Secondary Orbital Tumors Extending from Ocular |
|
|
|
or Periorbital Structures . . . . . . . . . . . . . . . . . . . . . . . . |
79 |
|
|
Roman Shinder and Bita Esmaeli |
|
|
7 |
Lacrimal Gland Tumors . . . . . . . . . . . . . . . . . . . . . . . . |
89 |
|
|
Brent Hayek and Bita Esmaeli |
|
|
8 |
Optic Nerve Sheath Fenestration in Cancer Patients: |
|
|
|
Indications and Surgical Technique . . . . . . . . . . . . . . . . . . |
103 |
|
|
Thomas E. Johnson |
|
|
9 |
Management of Primary Eyelid Cancers . . . . . . . . . . . . . . . |
113 |
|
|
Aaron Savar and Bita Esmaeli |
|
|
10 |
Management of Conjunctival Neoplasms . . . . . . . . . . . . . . . |
127 |
|
|
Stella K. Kim, Dan S. Gombos, and Bita Esmaeli |
|
|
11 |
Surgical Specimen Handling for Conjunctival |
|
|
|
and Eyelid Tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . |
139 |
|
|
Sheri L. DeMartelaere, Frank W. Scribbick, and Doina Ivan |
|
|
vii
viii |
|
Contents |
12 |
Neuroradiology of Ocular and Orbital Tumors . . . . . . . . . . |
. 149 |
|
J. Matthew Debnam |
|
13 |
Radiation Therapy for Orbital and Adnexal Tumors . . . . . . . . |
169 |
|
Steven J. Frank and Anita Mahajan |
|
Part II Intraocular Tumors
Section Editor: Dan S. Gombos
14 |
Multidisciplinary Management of Retinoblastoma: |
|
|
Diagnosis, Treatment, and Future Direction . . . . . . . . . . . . . |
179 |
|
Maurizio L. Ghisoli, Peter E. Zage, Cindy Herzog, Patty |
|
|
Chevez-Barrios, Murali Chintagumpala, Richard L. Hurwitz, |
|
|
Anita Mahajan, and Dan S. Gombos |
|
15 |
Management of Uveal Melanoma . . . . . . . . . . . . . . . . . . . |
201 |
|
Michelle Ludwig, Adam S. Garden, Michelle D.Williams, |
|
|
and Dan S. Gombos |
|
16 |
Uveal Metastases from Solid Tumors . . . . . . . . . . . . . . . . . |
215 |
|
Gerardo D. Camoriano and Dan S. Gombos |
|
17 |
Vascular Tumors of the Posterior Pole . . . . . . . . . . . . . . . . |
223 |
|
Dan S. Gombos |
|
Part III Oculoplastic and Periocular Reconstructive Surgery
in Cancer Patients
Section Editor: Bita Esmaeli
18 |
Reconstructive Surgery for Eyelid Defects . . . . . . . . . . . . . . |
231 |
|
Roman Shinder and Bita Esmaeli |
|
19 |
Nasolacrimal Duct Obstruction and Lacrimal Surgery |
|
|
in Cancer Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . |
243 |
|
Aaron Savar and Bita Esmaeli |
|
20 |
Eyelid Malposition: Unique Scenarios in Cancer Patients . . . . . |
251 |
|
Aaron Savar and Bita Esmaeli |
|
21 |
Craniofacial Surgery in the Orbit and Periorbital Region . . . . . |
259 |
|
Dominick Golio |
|
22 |
Enucleation, Evisceration, Orbital Implants, |
|
|
and Management of the Irradiated Socket . . . . . . . . . . . . . . |
275 |
|
Miguel Gonzalez-Candial and Aaron Savar |
|
23 |
Orbital Exenteration and Rehabilitation |
|
|
of the Exenterated Socket . . . . . . . . . . . . . . . . . . . . . . . |
285 |
|
Adam Hsu and Matthew M. Hanasono |
|
Contents |
ix |
|
24 |
Periorbital Surgical Rehabilitation After Facial |
|
|
Nerve Paralysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . |
295 |
|
Heather Chang, Mehryar Taban, and Tanuj Nakra |
|
25 |
Psychosocial Aspects of Orbitofacial Disfigurement |
|
|
in Cancer Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . |
311 |
|
Alessandro Bonanno and Jin Young Choi |
|
Part IV Ocular Side Effects of Cancer Therapy |
|
|
|
Section Editor: Bita Esmaeli |
|
26 |
Lacrimal and Canalicular Toxicity . . . . . . . . . . . . . . . . . . |
321 |
|
M. Amir Ahmadi and Bita Esmaeli |
|
27 |
Orbital and Periorbital Side Effects of Chemotherapy . . . . . . . |
327 |
|
John D. Ng |
|
28 |
Ocular and Orbital Infections in the Immunocompromised |
|
|
Cancer Patient . . . . . . . . . . . . . . . . . . . . . . . . . . . . . |
339 |
|
Viet H. Ho and Hao H. Ho |
|
Part V Neuro-ophthalmic Manifestations of Cancer
Section Editor: Jade S. Schiffman
29 |
Cranial Nerve III, IV, and VI Palsies in the Cancer Patient . . . . . |
355 |
|
Meghan S. Flemmons and Jade S. Schiffman |
|
30 |
Skull Base Tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . |
363 |
|
Anitha Raghunath and Jade S. Schiffman |
|
31 |
Optic Nerve Pathway Gliomas and Optic Nerve Meningiomas . . . |
383 |
|
Sonali Singh and Jade S. Schiffman |
|
32 |
Leptomeningeal Disease . . . . . . . . . . . . . . . . . . . . . . . . |
395 |
|
Gerardo D. Camoriano, Anitha Raghunath, |
|
|
and Jade S. Schiffman |
|
33 |
Paraneoplastic Visual Syndromes . . . . . . . . . . . . . . . . . . . |
407 |
|
Anitha Raghunath and Jade S. Schiffman |
|
34 |
Neurofibromatosis: Tumors of the Optic Pathway . . . . . . . . . . |
419 |
|
John M. Slopis and Jade S. Schiffman |
|
35 |
Other Optic Nerve Maladies in Cancer Patients . . . . . . . . . . . |
433 |
|
Jade S. Schiffman, Anitha Raghunath, and Rosa Ana Tang |
|
Part VI Common Vitreoretinal Conditions |
|
|
|
in Cancer Patients |
|
|
Section Editor: Bernard F. Godley |
|
x |
|
Contents |
36 |
Management of Endogenous Endophthalmitis . . . . . . . . . . . |
. 449 |
|
Kapil G. Kapoor, Gibran S. Khurshid, Garvin H. Davis, |
|
|
and Bernard F. Godley |
|
37 |
Viral Retinitis in the Cancer Patient . . . . . . . . . . . . . . . . |
. 459 |
|
Gibran S. Khurshid, Garvin H. Davis, Kapil G. Kapoor, |
|
|
and Bernard F. Godley |
|
38 |
Diagnostic Vitrectomy and the Cancer Patient: Special |
|
|
Considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . |
471 |
|
Garvin H. Davis, Gibran S. Khurshid, Kapil G. Kapoor, |
|
|
and Bernard F. Godley |
|
39 |
Intraocular Lymphoma: Current Therapy and Future Trends . . . 485 |
|
|
Christopher J. Calvano, Stella K. Kim, and Dan S. Gombos |
|
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . |
491 |
|
